- Home
- PTGX vs BEPC Comparison
PTGX vs BEPC Comparison
Compare PTGX & BEPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PTGX | BEPC |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 6.7B |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PTGX | BEPC |
|---|---|---|
| Price | $97.01 | $38.68 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 4 |
| Target Price | ★ $108.23 | $39.75 |
| AVG Volume (30 Days) | 462.9K | ★ 1.2M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 4.46% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $874.25 | $78.11 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2,055.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $49.86 | $30.45 |
| 52 Week High | $107.84 | $45.18 |
Technical Indicators
Market Signals| Indicator | PTGX | BEPC |
|---|---|---|
| Relative Strength Index (RSI) | 47.17 | 49.41 |
| Support Level | $96.36 | $37.19 |
| Resistance Level | $104.85 | $44.41 |
| Average True Range (ATR) | 4.25 | 1.13 |
| MACD | -0.26 | 0.20 |
| Stochastic Oscillator | 42.59 | 55.96 |
Price Performance
Historical ComparisonAbout PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
About BEPC Brookfield Renewable Corporation
Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia, and totals over 40 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners LP and Brookfield Renewable Corp.